A recent systematic review and network meta-analysis evaluate immune checkpoint inhibitor (ICI) combinations for driver gene-negative non-small cell lung cancer patients presenting with liver metastases. This subgroup historically experiences poor prognosis and suboptimal responses to immunotherapy. The synthesis of current trial data aims to inform optimized regimens that improve survival outcomes, signaling progress in tackling challenging metastatic lung cancer subsets.